ISIS 113715

DRUG5 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

Type 2 Diabetes Mellitus

Phase 1

Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715

CompletedNCT00365781

Ionis Pharmaceuticals, Inc.Type 2 Diabetes Mellitus

Start: 2006-08-31End: 2006-09-30Target: 10Updated: 2007-10-17

Phase 2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

WithdrawnNCT00327626

Ionis Pharmaceuticals, Inc.Type 2 Diabetes Mellitus

Start: 2006-05-01End: 2007-03-01Updated: 2022-12-05

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

TerminatedNCT00330200

Ionis Pharmaceuticals, Inc.Type 2 Diabetes Mellitus

Start: 2005-11-01End: 2007-03-01Updated: 2022-12-05

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

CompletedNCT00330330

Ionis Pharmaceuticals, Inc.Type 2 Diabetes Mellitus

Start: 2003-02-28End: 2006-08-31Target: 96Updated: 2008-02-06

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

CompletedNCT00455598

Ionis Pharmaceuticals, Inc.Type 2 Diabetes Mellitus

Start: 2007-02-28End: 2009-05-31Updated: 2009-08-28

Related Papers

Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells

Nucleic Acid Therapeutics2022-08-1716 citations